Shots:

• The P-III ENSURE (1 &2) program evaluates IMU-838 (30mg- qd) vs PBO in ~ 1-050 patients with active RMS. The 1EPs of both trials is time to 1st relapse @72wks. & 2EPs include a volume of T2-lesions- time to confirm disability progression- changes in cognition & measure brain volume
• The P-II CALLIPER trial assess IMU-838 (45mg) vs PBO in ~450 patients with PMS. The 1EPs of a trial is a change is an annualized rate of percent brain volume change up to 120wks. & 2EPs include a change in whole-brain atrophy & disability progression
• The company expects to initiate ENSURE & CALLIPER trial in H2’21 while dosing of 1st patient in CALLIPER trial is expected in Q3’21 & ENSURE trials in H2’21

  | Ref: Immunic | Image: Immunic